Thrombotic microangiopathies

New England Journal of Medicine

Volumn 347, Issue 8, 2002, Pages 589-600

  Moake, Joel L ^a,b  

^a RICE UNIVERSITY   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H;

CLINICAL FEATURE; COMPLEMENT DEFICIENCY; HEMOLYTIC UREMIC SYNDROME; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BLOOD COMPONENT TRANSFUSION; COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; METALLOENDOPEPTIDASES; PLATELET ACTIVATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 0037158606     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020528     Document Type: Review

References (107)

1. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease
2. Hämolytischurämische syndrome: Bilaterale nierenrindennekrosen bei akuten erworbenen hämolytischen anämien schweizerische
3. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
4. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli
5. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura
6. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature
7. Renal function in Inuit survivors of epidemic hemolytic-uremic syndrome
8. The late histologic findings in diarrhea-associated hemolytic uremic syndrome
9. The hemolytic uremic syndrome of childhood and its variants
10. Cytotoxin-producing Escherichia coli and the hemolytic uremic syndrome
11. Familial hemolytic uremic syndrome associated with complement factor H deficiency
12. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Clinical experience in 108 patients
13. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
14. Haemolytic-uraemic syndrome: Basic science
15. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura
16. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
17. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease
18. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: Evolving concepts of pathogenesis and therapy
19. Late relapses in individuals successfully treated for thrombotic thrombocytopenic purpura
20. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
21. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura
22. Thrombotic thrombocytopenic purpura associated with clopidogrel
23. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP)
24. Genetic studies into inherited and sporadic hemolytic uremic syndrome
25. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency
26. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura
27. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen
28. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura
29. Developing basic and clinical research on von Willebrand factor and von Willebrand disease
30. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation
31. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: Studies using optical tweezers
32. Shear stress-induced binding of von Willebrand factor to platelets
33. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
34. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
35. Partial amino acid sequence of purified von Willebrand factor-cleaving protease
36. Purification of von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family
37. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
38. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura
39. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma
40. Endothelial von Willebrand factor multimers form extremely long strings that are efficiently cleaved by constituents of normal plasma but not of plasma from patients with thrombotic thrombocytopenic purpura
41. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells
42. Control of von Willebrand factor multimer size by thrombospondin-1
43. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome
44. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
45. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
46. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome
47. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura
48. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases
49. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies
50. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor
51. Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease
52. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura
53. The United States National Progressive Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings
54. Pathogenesis of Shiga toxin (verotoxin)-induced endothelial cell injury
55. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1
56. Shiga toxin 1 elicits diverse biologic responses in mesangial cells
57. Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2
58. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome
59. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome
60. Cluster of cases of haemolytic uraemic syndrome due to unpasteurised cheese
61. Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins
62. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells
63. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression
64. Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: Possible involvement in the production of TNF-alpha
65. A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures
66. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells
67. Glomerular endothelial cell injury mediated by Shiga-like toxin-1
68. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells
69. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome
70. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome
71. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin
72. Verotoxin-l-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress
73. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome
74. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
75. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome
76. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome
77. Neutrophil elastases and haemolytic uraemic syndrome
78. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood
79. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome
80. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets
81. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome
82. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities
83. Recurrence of renal disease after kidney transplantation in children: 24 Years of experience in a single center
84. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H
85. Human complement factor H deficiency associated with hemolytic uremic syndrome
86. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome
87. Hemolytic uremic syndrome: How do factor H mutants mediate endothelial damage?
88. The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20
89. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition
90. Hemolytic uremic syndrome and complement factor H deficiency: Clinical aspects
91. Thrombotic microangiopathies associated with drugs and bone marrow transplantation
92. Hemolytic uremic syndrome in solid-organ transplant recipients
93. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: A new clinical entity
94. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes
95. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease
96. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura
97. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura
98. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic
99. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura
100. Treatment of thrombotic thrombocytopenic purpura with vincristine
101. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura
102. Haemolytic uraemic syndrome: Therapeutic effect of plasma infusion
103. Failure of fresh frozen plasma infusions to alter the course of hemolytic-uremic syndrome
104. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion
105. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents
106. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies
107. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome